The Corneal Graft Rejection drugs in development market research report provides comprehensive information on the therapeutics under development for Corneal Graft Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Corneal Graft Rejection. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Corneal Graft Rejection and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Corneal Graft Rejection by nine companies/universities/institutes. The top development phase for Corneal Graft Rejection is preclinical with seven drugs in that stage. The Corneal Graft Rejection pipeline has eight drugs in development by companies and one by universities/ institutes. Some of the companies in the Corneal Graft Rejection pipeline products market are: Elasmogen, CalciMedica and Gene Signal International.
The key targets in the Corneal Graft Rejection pipeline products market include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16), Insulin Receptor Substrate 1 (IRS1), and ICOS Ligand (B7 Homolog 2 or B7 Like Protein Gl50 or B7 Related Protein 1 or CD275 or ICOSLG).
The key mechanisms of action in the Corneal Graft Rejection pipeline product include Calcineurin (Protein Serine/Threonine Phosphatase 3 or Protein Phosphatase 3 or EC 3.1.3.16) Inhibitor with two drugs in Phase I. The Corneal Graft Rejection pipeline products include five routes of administration with the top ROA being Ophthalmic and four key molecule types in the Corneal Graft Rejection pipeline products market including Small Molecule, and Antisense Oligonucleotide.
Corneal Graft Rejection overview
Corneal graft rejection comprises a sequence of complex immune responses that involves the recognition of the foreign histocompatibility antigens of the corneal graft by the host’s immune system, leading to the initiation of the immune response cascade. An efferent immune response is mounted by the host immune system against these foreign antigens culminating in rejection and graft decompensation in irreversible cases
For a complete picture of Corneal Graft Rejection’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
